How biopharma sponsors can design harmonized global regulatory filing strategies while navigating diverging regional requirements between FDA, EMA, and PMDA.
Read the full white paper for complete data and regulatory guidance →
SSI Strategy: Global Submissions Strategy – Aligning for Divergence in Oncology Drug Development
